Lorlatinib - LORVIQUA®
According to the NCI website, lorlatinib is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)
Indikationen/Anwendungsmöglichkeiten gemäss Compendium®:
- Lorviqua kann angewendet werden zur Behandlung von erwachsenen Patienten mit Anaplastische-Lymphom-Kinase (ALK)-positivem, metastasiertem nicht kleinzelligem Lungenkarzinom (non small cell lung cancer, NSCLC) nach Progression unter vorangegangener Behandlung mit mindestens zwei ALK-Tyrosinkinaseinhibitoren (TKI).
Merkblätter für Patientinnen und Patienten (Stand 6.4.20: noch nicht erhältlich)
Link zur Fachinformation des Compendium®:
Medikamenteniformation: Für den Arzt Patienteninformation
More information in English:
Link to National Cancer Institute
Link to Wikipedia
Link zu PharmaWiki
Link to European Medicines Agency (EMEA)
Link to Physicians Desk Reference (PDR)
Link to Wikipedia
Link zu PharmaWiki
Link to European Medicines Agency (EMEA)
Link to Physicians Desk Reference (PDR)
More information for patients:
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Info for Patients presented by Scott Hamilton from Chemocare.com
Info for Patients presented by Scott Hamilton from Chemocare.com